Immunohistochemistry Market to Grow with a CAGR of 6.90% through 2030

Rising Incidence of Chronic and Infectious Diseases and Growth in Geriatric Population are expected to drive the Global Immunohistochemistry Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Immunohistochemistry Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Immunohistochemistry Market stood at USD 2.38 Billion in 2024 and is anticipated to grow with a CAGR of 6.90% in the forecast period, 2026-2030.

The global shift toward personalized medicine anchored in tailoring therapies based on individual biomarker profiles has significantly elevated the strategic role of immunohistochemistry (IHC). In oncology, for instance, the detection of HER2, ER, and PR receptor status via IHC is now foundational for guiding therapeutic decisions in breast cancer. As healthcare systems and pharmaceutical pipelines increasingly prioritize precision treatment models, the demand for IHC-based companion diagnostics and patient stratification tools continues to expand.

Contract Research Organizations (CROs) and pharmaceutical innovators are intensifying their focus on translational research and early-phase drug development, both of which heavily utilize IHC. From validating therapeutic targets to assessing pharmacodynamics and conducting toxicological profiling, IHC serves as a core analytical tool. The rise in global clinical trial activity particularly in oncology and immunotherapy has directly translated into heightened demand for IHC reagents, imaging systems, and pathology support services. Rapid infrastructure upgrades across healthcare systems in high-growth economies such as China, India, and Brazil are accelerating the adoption of advanced diagnostic technologies. Government-led initiatives and private sector investment are fueling the establishment of specialized diagnostic centers and tertiary care hospitals, many of which integrate IHC for high-accuracy histopathological assessments. As diagnostic capabilities scale up in these regions, IHC is becoming a standard component of routine pathology workflows.

Universities, medical schools, and research institutes are increasingly embedding IHC into foundational and applied life science research. Its utility spans diverse domains, including neuroscience, developmental biology, and immunopathology. The proliferation of grant funding, public-private partnerships, and international research consortia has reinforced IHC’s role as a key methodology in experimental design and tissue analysis, thereby extending its influence beyond the clinical realm. In several mature healthcare markets, regulatory agencies and payers are actively facilitating IHC adoption through supportive policy measures. Agencies such as the U.S. FDA are promoting the development and commercialization of IHC-based companion diagnostics aligned with targeted therapies. In parallel, reimbursement structures for pathology services increasingly cover IHC procedures, reducing cost-related adoption barriers and encouraging broader clinical deployment.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Immunohistochemistry Market”

Global Immunohistochemistry Market is segmented into product, application, end user, regional distribution, and company.

Based on its end user, the Hospitals & Diagnostic Laboratories segment has emerged as the predominant market leader, Hospitals and diagnostics labs handle most tissue-based diagnostics, particularly in oncology, where IHC is routinely employed to determine tumor classification, receptor status, and treatment pathways. Large tertiary and quaternary hospitals conduct thousands of biopsy assessments daily, integrating IHC into standard pathology protocols. Diagnostic laboratories process bulk sample volumes, often from both public and private healthcare providers, ensuring consistent demand for IHC reagents and instruments. This high volume of testing solidifies their position as the primary consumer of IHC solutions.

Hospitals serve as referral centers for cancer diagnosis and care, where IHC plays a vital role in identifying biomarkers such as HER2, Ki-67, PD-L1, and others critical for targeted therapy selection. IHC is essential for tumor subtyping, grading, and staging, directly influencing surgical, chemotherapeutic, and immunotherapeutic strategies. Comprehensive cancer centers and pathology departments are increasingly adopting automated IHC platforms, digital slide scanners, and AI-based interpretation tools to streamline workflows and improve accuracy. Their pivotal function in oncology care directly drives investment in IHC infrastructure and personnel training. As the healthcare industry transitions toward precision medicine, hospitals and laboratories are prioritizing investment in advanced diagnostic modalities like IHC. Many hospitals are establishing in-house molecular pathology labs equipped with IHC automation systems to reduce turnaround time and ensure quality control. Strategic partnerships between hospitals and diagnostic technology providers support custom assay development and companion diagnostic deployment, further embedding IHC in clinical operations. This trend is particularly evident in developed markets such as North America and Western Europe, where hospitals are early adopters of diagnostic innovation.

Based on region, The Asia Pacific region is experiencing rapid market growth. Governments across Asia Pacific are aggressively modernizing healthcare delivery systems through strategic investments in diagnostic laboratories, specialty hospitals, and public health programs. National health initiatives, such as Ayushman Bharat in India and Healthy China 2030, emphasize accessible cancer screening and diagnostics. The establishment of centralized pathology labs and regional cancer centers is enhancing the reach and utilization of IHC technologies in urban and semi-urban areas. This expanding infrastructure base provides fertile ground for IHC market penetration.

Asia Pacific has emerged as a hub for pharmaceutical manufacturing, clinical trials, and contract research, which heavily rely on IHC for drug discovery, biomarker validation, and histological evaluation. Major CROs and pharma companies are setting up research facilities across India, China, South Korea, and Singapore, where IHC is a core tool in translational and regulatory studies. The region’s cost-efficiency and patient diversity are attracting global clinical trial sponsors, further boosting IHC usage in investigational protocols. This R&D momentum is contributing significantly to regional demand for IHC reagents, antibodies, and imaging systems. Asia Pacific healthcare systems are undergoing a paradigm shift from generalized treatment to biomarker-driven therapies, particularly in oncology and immunotherapy. With the rising availability of targeted drugs and companion diagnostics, IHC is becoming essential for therapy selection, monitoring, and stratification. Countries like Japan and South Korea are leading early adopters of IHC-linked precision oncology programs, supported by favorable reimbursement and regulatory clarity. As personalized medicine gains traction, IHC becomes an indispensable diagnostic pillar.

Major companies operating in Global Immunohistochemistry Market are:

• Thermo Fisher Scientific Inc
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• Danaher Corporation
• PerkinElmer U.S. LLC
• Bio-Rad Laboratories, Inc.
• Cell Signaling Technology, Inc.
• Bio SB
• Agilent Technologies, Inc.
• Abcam Limited

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Immunohistochemistry Market is undergoing a significant transformation, driven by advancements in precision diagnostics, the rising global cancer burden, and growing adoption across research and clinical settings. As pharmaceutical innovation accelerates and healthcare systems increasingly prioritize personalized medicine, IHC has become an essential tool for biomarker discovery, companion diagnostics, and targeted therapy decision-making. With robust demand from hospitals, diagnostic labs, and research institutions and rapid expansion in high-growth regions such as Asia Pacific the market is well-positioned for sustained growth. Stakeholders who invest in innovation, automation, and strategic global partnerships will be best equipped to capitalize on the market’s evolving opportunities and competitive landscape.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Immunohistochemistry Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Antibodies, Equipment, Reagents, Kits), By Application (Diagnostics, Cancer, Infectious Diseases, Cardiovascular Diseases, Autoimmune Diseases, Diabetes Mellitus, Nephrological Diseases, Research), By End User (Hospitals & Diagnostic Laboratories, Research Institutes, Others), By Region & Competition, 2020-2030F”, has evaluated the future growth potential of Global Immunohistochemistry Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Immunohistochemistry Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: [email protected]